» Articles » PMID: 27869648

Hippo Signaling Interactions with Wnt/β-catenin and Notch Signaling Repress Liver Tumorigenesis

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2016 Nov 22
PMID 27869648
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant tumors develop through multiple steps of initiation and progression, and tumor initiation is of singular importance in tumor prevention, diagnosis, and treatment. However, the molecular mechanism whereby a signaling network of interacting pathways restrains proliferation in normal cells and prevents tumor initiation is still poorly understood. Here, we have reported that the Hippo, Wnt/β-catenin, and Notch pathways form an interacting network to maintain liver size and suppress hepatocellular carcinoma (HCC). Ablation of the mammalian Hippo kinases Mst1 and Mst2 in liver led to rapid HCC formation and activated Yes-associated protein/WW domain containing transcription regulator 1 (YAP/TAZ), STAT3, Wnt/β-catenin, and Notch signaling. Previous work has shown that abnormal activation of these downstream pathways can lead to HCC. Rigorous genetic experiments revealed that Notch signaling forms a positive feedback loop with the Hippo signaling effector YAP/TAZ to promote severe hepatomegaly and rapid HCC initiation and progression. Surprisingly, we found that Wnt/β-catenin signaling activation suppressed HCC formation by inhibiting the positive feedback loop between YAP/TAZ and Notch signaling. Furthermore, we found that STAT3 in hepatocytes is dispensable for HCC formation when mammalian sterile 20-like kinase 1 and 2 (Mst1 and Mst2) were removed. The molecular network we have identified provides insights into HCC molecular classifications and therapeutic developments for the treatment of liver tumors caused by distinct genetic mutations.

Citing Articles

The Role of Yes-Associated Protein in Inflammatory Diseases and Cancer.

Zhong B, Du J, Liu F, Sun S MedComm (2020). 2025; 6(3):e70128.

PMID: 40066231 PMC: 11892025. DOI: 10.1002/mco2.70128.


Molecular mechanisms of Hippo pathway in tumorigenesis: therapeutic implications.

Saadh M, Ahmed H, Kareem R, Kumar Bishoyi A, Roopashree R, Shit D Mol Biol Rep. 2025; 52(1):267.

PMID: 40014178 DOI: 10.1007/s11033-025-10372-y.


Molecular Insights into Ischemia-Reperfusion Injury in Coronary Artery Disease: Mechanisms and Therapeutic Implications: A Comprehensive Review.

Ghanta S, Kattamuri L, Odueke A, Mehta J Antioxidants (Basel). 2025; 14(2).

PMID: 40002399 PMC: 11851988. DOI: 10.3390/antiox14020213.


Decoding gene expression profiles of Hippo signaling pathway components in breast cancer.

Bhavnagari H, Shah F Mol Biol Rep. 2025; 52(1):216.

PMID: 39928181 DOI: 10.1007/s11033-025-10299-4.


Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.


References
1.
Zhou D, Conrad C, Xia F, Park J, Payer B, Yin Y . Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16(5):425-38. PMC: 3023165. DOI: 10.1016/j.ccr.2009.09.026. View

2.
Halder G, Dupont S, Piccolo S . Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol. 2012; 13(9):591-600. DOI: 10.1038/nrm3416. View

3.
Yimlamai D, Christodoulou C, Galli G, Yanger K, Pepe-Mooney B, Gurung B . Hippo pathway activity influences liver cell fate. Cell. 2014; 157(6):1324-1338. PMC: 4136468. DOI: 10.1016/j.cell.2014.03.060. View

4.
Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

5.
Yimlamai D, Fowl B, Camargo F . Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015; 63(6):1491-501. PMC: 4654680. DOI: 10.1016/j.jhep.2015.07.008. View